RC Outsourcing, LLC, Lowellville, OH

Is RC Outsourcing, LLC registered with the FDA as a 503B outsourcing facility?

Record found. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names RC Outsourcing, LLC in Lowellville, OH, first registered Oct 7, 2015 and most recently registered Nov 27, 2025.

Does RC Outsourcing, LLC hold a Ohio pharmacy license?

State board of pharmacy records for Ohio are not checked: the board’s website rejected automated requests and the state’s eLicense lookup answers them with a script check, and this index does not work around blocks. The Delaware Division of Professional Regulation also lists nonresident license AD-0000051 for RC Outsourcing, LLC, LOWELLVILLE, OH, status Active, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301012343 for RC Outsourcing LLC, Lowellville, OH, status Active, as of Nov 10, 2026.

Has RC Outsourcing, LLC had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Mar 20, 2026) and 1 FMD-145 letter (May 22, 2020) for RC Outsourcing, LLC. State board of pharmacy records for Ohio are not checked: the board’s website rejected automated requests and the state’s eLicense lookup answers them with a script check, and this index does not work around blocks.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
RC Outsourcing, LLC; RC Outsourcing LLC
Location
Lowellville, OH
Type as FDA labels it
503B
FDA 503B list
Listed as RC Outsourcing, LLC
Form 483s on FDA’s actions page
5
Warning letters on FDA’s actions page
1
Latest action on that page
Sep 3, 2026
FDA Data Dashboard inspections
6 inspections: 4 OAI, 2 VAI; 9 published Form 483s
Form 483 text on this page
5 Form 483s, 43 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as RC Outsourcing LLC, a 503B facility, with 8 dated actions.

Document
Sep 3, 2026Form 483483 Issued 09/03/2026fda.gov
Mar 20, 2026Warning letterWarning Letter (03/20/2026)fda.gov
Aug 28, 2025Form 483483 Issued 08/28/2025fda.gov
Sep 27, 2024Form 483483 Issued 09/27/2024fda.gov
Jul 25, 2023Regulatory meetingRegulatory Meeting Held 07/25/2023Not linked by FDA
Sep 23, 2022Form 483483 Issued 09/23/2022fda.gov
May 22, 2020FMD-145 letterFMD-145 Letter Issued 05/22/2020FDA copy (archived)
Feb 8, 2019Form 483483 Issued 02/08/2019fda.gov

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists RC Outsourcing, LLC, Lowellville, OH (FEI number 3011967886), matched to this page by exact name, city and state. It lists 6 inspections: 4 OAI, 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Aug 28, 2025Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30119678861279818
Sep 27, 2024Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30119678861252006
Sep 23, 2022Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30119678861180214
Feb 8, 2019Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30119678861081262
Mar 31, 2017Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30119678861007167
Feb 9, 2016Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)3011967886959784

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 43 numbered observations in all, across 5 inspections ending Mar 31, 2017 to Sep 3, 2026. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Aug 24, 2026 to Sep 3, 2026: 8 observations

Firm on the cover
RC Outsourcing, LLC, 102 E Water St, Lowellville, OH 44436-1117
FEI number
3011967886
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
550 Main Street, Ste 4930 Cincinnati, OH 45202
Matched to this page by
FEI number on the cover; linked from actions page, 503B list, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.

Specifically,

A. Your firm conducted Airflow Visualization (AFV) studies (smoke studies) for ISO 5 Laminar Flow Hood <Redacted B4> and Laminar Flow Hood <Redacted B4> under both static and dynamic conditions in August 2025 and February 2026. No formal study reports or supporting documentation were available for review for either study. The records lacked the following critical study elements: the type of smoke sources, the stated study purpose, targeted test locations, and personnel activities performed during dynamic conditions, real-time observations, and conclusions. Although video recordings of the AFV studies were captured, they were not accompanied by written protocols, contemporaneous documentation, or summary reports sufficient to contextualize, interpret, or substantiate the visual findings.

B. ...

Read the full 483 (PDF on fda.gov)

Observation 2

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically,

Sterility test failure investigations for aseptically re-packaged Avastin 1.25 mg/0.05 mL were inadequate and failed to identify probable root causes. Since October 2025, the firm has rejected four batches due to sterility failures. Despite the rejection of these batches, other batches manufactured on the same day and in the same laminar flow hood in the table below were released without a scientifically sound justification or supporting data demonstrating adequate risk mitigation.

failures. Despite the rejection of these batches, other batches manufactured on the same day and in the same laminar flow hood in the table below were released without a scientifically sound justification or supporting data demonstrating adequate risk mitigation.

Fill date Rejected lot #

Released lot manufactured in the same hood

Released lots manufactured in the 2nd hood

120251017-01A42E

120251017-0FFE8B 120251017-6D87A8 10151017-03F240 120251017-235C2A ...

Read the full 483 (PDF on fda.gov)

Observation 3

Separate or defined areas to prevent contamination or mix-ups are deficient regarding the manufacturing and processing operations.

Specifically,

A. Personnel and material flow into and out of the ISO 7 and ISO 8 classified areas occurs through a single shared pathway that passes directly through the visual inspection and labeling room. Gowning, degowning, and material transfer -including finished product exiting the cleanroom and incoming components entering -all traverse the same corridor used for labeling and visual inspection of previously released product, creating a convergence of traffic that is inconsistent with unidirectional flow principles. Specifically, operators completing shoe covers, head covers, masks, and hand washing in the non­classified area must traverse this shared labeling room pathway to reach the ISO 8 entry door. Upon degowning, operators must similarly walk from ISO 7, through ISO 8, and through this same labeling room, where other staff are actively performing packaging, labeling, and visual inspection activities, to reach an outside corridor. No designated degowning area exists within the ISO 8 anteroom. ...

Read the full 483 (PDF on fda.gov)

Observation 4

There is a lack of written procedures assigning responsibility, providing cleaning schedules and describing in sufficient detail the methods, equipment and materials to be used for sanitation.

Specifically,

A. Your firm's cleaning procedure is inadequate.

i. Your firm stated that only the ISO 5 laminar flow hood receives cleaning <Redacted B4>. However, your firm failed to clean the ISO 7 classified area <Redacted B4> leaving cleaning to the end of production for the day.

ii. Your firm lacks scientifically established and data-supported cleaning intervals for the cleanroom. A review of cleaning records revealed a 49-day gap between the <Redacted B4> deep cleaning performed on 02/09/2026 and the subsequent cleaning on 03/30/2026. Furthermore, your firm acknowledged that scheduling cleaning on a <Redacted B4> basis -rather than at fixed intervals -could permit up to <Redacted B4> between cleaning events. ...

Read the full 483 (PDF on fda.gov)

Observation 5

Routine calibration, inspection and checking of automatic, mechanical and electronic equipment is not performed according to a written program designed to assure proper performance.

Specifically,

Your firm has not performed temperature mapping under the worst-case conditions for your critical equipment during equipment qualification.

For example, your firm operates < Redacted B4> incubators <Redacted B4>; <Redacted B4> refrigerators <Redacted B4> all of which are used for product storage and environmental monitoring (EM) sample incubation. A review of the initial qualification records for these units revealed that temperature mapping was performed exclusively under empty-state conditions. When asked whether temperature mapping under operationally loaded conditions had been performed to reflect the units' current operational use, your firm confirmed that only the initial empty-state mapping had been completed and no subsequent studies have been initiated.

Observation 6

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically,

Your firm continues to fail to provide a scientific rationale to support the established method and limits for subvisible particle testing of Avastin (bevacizumab) 1.75 mg/0.07 mL for intravitreal injection. Your firm releases this product using a subvisible particulate matter specification of <Redacted B4> particles/container at <Redacted B4> and <Redacted B4> particles/container at <Redacted B4>. <Redacted B4> lots associated with endophthalmitis adverse events were released using this particulate matter specification.

This observation is a repeat observation from the previous FDA 483, List of Observations, issued on 11/04/2024.

Observation 7

Employees are not given training in the particular operations they perform as part of their function, current good manufacturing practices and written procedures required by current good manufacturing practice regulations.

Specifically,

A. Your firm does not conduct periodic CGMP training for employees.

B. Not all personnel receive basic training on the theory and practice of the Quality Management System and Good Manufacturing Practices, as required, per SOP-6 Training and Personnel, v2.0, effective September 30, 2025, Section 5.2.1.

C. Your firm has not established training or qualification requirements to ensure that personnel responsible for reading and interpreting EM plate results are able to accurately enumerate and differentiate microbial growth and surface colonization.

Observation 8

Drug product expiration dates are not related to the storage conditions stated on the labeling, as determined by stability studies.

Specifically,

Your firm's product labels do not specify required storage temperature conditions, and the assigned <Redacted B4> beyond-use date (BUD) is not supported by stability testing.

For example: your firm has failed to specify required storage temperature conditions on product labels, despite assigning a <Redacted B4> beyond-use date (BUD). For example, your firm stated that stability testing is not conducted for its non-sterile compounded products on the basis that the water activity content is less than <Redacted B4>%, with a <Redacted B4> BUD assigned at a controlled room temperature ot <Redacted B4>. However, all three non-sterile product labels reviewed during the inspection indicated only "room temperature," without further qualification or specification of the required temperature range, which is inconsistent with your firm's stated storage conditions.

ofthe required temperature range, which is inconsistent with your firm's stated storage conditions.

Inspection Aug 18, 2025 to Aug 28, 2025: 8 observations

Firm on the cover
RC Outsourcing, LLC, 102 E Water St, Lowellville, OH 444 36-1117
FEI number
3011967886
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
550 Main Street, Ste 4930 Cincinnati, OH 45202
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Investigations of a failure of a batch or any of its components to meet any of its specifications did not extend to other batches of the same drug product and other drug products that may have been associated with the specific failure or discrepancy.

Specifically, Lot # #20250428-488A81 of Avastin® (bevacizumab) re-packaged on April 28, 2025, failed sterility testing. Non-Conformance Report NCR-2 identified the potential root cause as a medical condition the technician who re-packaged the lot was experiencing and failed to report. Your investigation resulted in the rejection of this lot. You did not extend the investigation to other lots re-packaged by the same technician. From April 21 , 2025 to July 21, 2025, the technician re-packaged approximately <Redacted B4> lots of Avastin® (bevacizumab), including the lot that failed sterility testing. In addition, your firm failed to implement appropriate corrective action in that once you were informed of the issue you allowed the technician to continue working in the cleanroom before resolution of the medical condition .

Observation 2

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically, your firm has not developed an environmental monitoring plan based upon sound scientific methods to include appropriate sampling frequency and timing. Your firm has no documentation to demonstrate that the environmental sampling performed is representative of the entire process. For example,

documentation to demonstrate that the environmental sampling performed is representative of the entire process. For example,

a) Your firm is taking <Redacted B4> active viable air <Redacted B4> towards the <Redacted B4> of filling. Filling operations for Avastin® (bevacizumab) can take <Redacted B4>. In addition, the active air sampler is placed outside of the laminar flow hood facing into the flow of the air. Your firm has no documentation to demonstrate that this sampling method is representative of ISO 5 conditions within the laminar flow hood. This is a repeat observation from the 09/17-27/2024 inspection.

b) On August 18, 2025, I observed the passive air plates were placed in the far corner of each laminar flow hood. ...

Read the full 483 (PDF on fda.gov)

Observation 3

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.

Specifically, from October 1, 2024 to present your firm personnel have had approximately 43 instances of microbial recovery on sleeves. These include four (4) instances where 3CFU were recovered and one (1) instance where 2CFU were recovered . All others were 1CFU. None of these recoveries have been investigated since they were <Redacted B4> your action limit. Your firm failed to identify and investigate this adverse trend in personnel monitoring.

None of these recoveries have been investigated since they were [ 6) (4 ~ your action limit. Your firm failed to identify and investigate this adverse trend in personnel monitoring.

Observation 4

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically, tips and caps for dropper bottles are placed directly onto the surface of the LFH when filling Povidone-lodine (re-packaging Betadine).

Work Instruction Wl-22 Production Protocol for Repackaging Betadine (12ovidone-iodine) 5% Oohthalmic Solution in Sterile Droooer Bottles, version I3.0 effective 2025-02-14, states under section 5.3 Production Tasks: "6. Open <Redacted B4> of the dropper bottles. Remove <Redacted B4> from the package. Remove the <Redacted B4>

The batch record for the filling of Povidone-lodine (re-packaging Betadine) also states under one of the Production Tasks to "Remove dropper bottles from the package and <Redacted B4> <Redacted B4> and set them with the <Redacted B4> to the <Redacted B4> of the holders".

This is a repeat observation from the 09/17-27/2024 inspection.

Observation 5

Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.

Specifically, test methods used by your contract testing lab for determining assay for the Lidocaine 23%-Tetracaine 7% ointment (LT), Lidocaine, USP 20%-Tetracaine, USP 6%-Phenylephrine, HCI 2% ointment (LTP), and the Benzocaine 20%-Lidocaine 6%-Tetracaine 4% ointment (BLT) are not validated. The Certificate of Analysis (CoA) from the contract testing lab states for the analysis of Tetracaine, Benzocaine and Phenylephrine that the potency method(s) used passed system suitability requirements for "non-cGMP analysis" and that "product specific method validation is not available for this sample and specification(s) are for informational purposes only". Since October 1, 2024, your firm has made approximately <Redacted B4> lots of the BLT stock, <Redacted B4> lots of the LT stock, and <Redacted B4> lots of the LTP stock.

Observation 6

Reports of analysis from component suppliers are accepted in lieu of testing each component for conformity with all appropriate written specifications, without performing at least one specific identity test on each component and establishing the reliability of the supplier's analyses through appropriate validation of the supplier's test results at appropriate intervals.

Specifically, your firm is compounding Lidocaine HCI 2% Solution injection, Lidocaine 23%-Tetracaine 7% ointment (LT), Lidocaine, USP 20%-Tetracaine, USP 6%-Phenylephrine, HCI 2% ointment (LTP), and the Benzocaine 20%-Lidocaine 6%-Tetracaine 4% ointment (BLT) from bulk drug substances. Your firm does not perform any testing, including an identity test, on the incoming bulk drug substances or excipients used to make these products.

Observation 7

Routine calibration of automatic, mechanical and electronic equipment is not performed according to a written program designed to assure proper performance.

Specifically, your firm is not calibrating the balances used to weigh bulk drug substances and excipients used to make Lidocaine HCI 2% Solution injection, Lidocaine 23%-Tetracaine 7% ointment (LT), Lidocaine, USP 20%-Tetracaine, USP 6%-Phenylephrine, HCI 2% ointment (LTP), and the Benzocaine 20%-Lidocaine 6%-Tetracaine 4% ointment (BLT). Your personnel perform a verification before use using uncalibrated weights. Of the three (3) technicians I spoke to, each performed this verification in a manner that was not consistent with Wl-16 Calibration and O12eration of a Precision Balance, version 1.0 effective 2024-10-28. In addition, the verification performed when making the Lidocaine 2% Solution injection is not documented. No other calibration of the balances is performed.

Observation 8

Batch production and control records do not include complete information relating to the production and control of each batch .

Specifically, your firm is not recording all pertinent information regarding raw materials, equipment and consumables used during the compounding of drug products. For example,

a) Your firm does not record the lot number of the sterile disposable beakers used to make the Lidocaine 2% Injection.

b) Your firm did not record in the batch record the lot number of the <Redacted B4> used for lot #20240725-0C03FA of Lidocaine 2% Solution injection.

Inspection Sep 17, 2024 to Sep 27, 2024: 8 observations

Firm on the cover
RC Outsourcing, LLC, 102 E Water St, Lowellville, OH 44436-1117
FEI number
3011967886
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
550 Main Street, Ste 4930 Cincinnati, OH 45202
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically,

Environmental monitoring (EM) is conducted for every batch including active air, work surfaces and gloved hands. However, your EM program is inadequate for the following:

A. No EM is required for gowns during aseptic processing. Given that one operator is responsible for producing a batch in each ISO 5 LAFW, during the production of Avastin 1.75 mg/0.07 mL, Lot# <Redacted B4>, it was observed that the operator moved finished syringes out of the ISO 5 LAFW and introduced supplies, such as syringes and caps, into the ISO 5 LAFW regularly. The operators' sleeves were exposed to the ISO 7 environment. Additionally, gowning was conducted in the ISO 8 anteroom. However, no EM is required to be performed on the sleeves inside the ISO 5 LAFW during aseptic processing, as per SOP-57, Testing of Sterile Environment, Version 1.0, Effective Date: 8/16/2024.

B. The EM monitoring of non-viable particles and active air sampling are inadequate. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Specifically,

All EM raw data are recorded in an Excel sheet without a secondary review process in place.

Your firm conducts EM for an active air sample, a surface sample, and fingertip samples from both the left and right gloved hands during the production ofeach batch. All <Redacted B4> plates are read by the quality director and the results are recorded in an Excel sheet. However, the raw EM data can be altered in the Excel sheet, and no secondaiy review process exists for the raw data.

Observation 3

There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically,

Your firm did not investigate failures of initial visual inspections. Since 2023, your fnm has reported the initial 100% visual inspection failures for seven batches due to defects ( e.g. black paiticles or white particles) exceeding the acceptable limit. Even though reinspection yielded passing results, your firm failed to investigate the out-of-specification (OOS) results. For example, the visual inspection of Avastin 2.0 mg/0.08 mL, Loot# <Redacted B4> Manufacturing Date: 11/21/2023 identified 48 white particles (Major) , exceeding the liinit of Majot <Redacted B4>) as defined in SOPP 4. 7.1.2, Prepai·ation -Testing -Visual Inspection for Visible Particulate - Al 1Compounded Preparations, Issue Date: 1/28/2020. The batch was released after a reinspection showed passing results, ; however, no investigation has been conducted for this OOS result.

Observation 4

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications designed to assure that conform to appropriate standards of identity, strength, quality and purity.

Specifically,

Your firm failed to provide scientific rationale to support established liinits for subvisible particles in Avastin 2.5 mg/0.1 mL and Avastin l .75mg/0.07mL. For example, your firm currently manufactures Lidocaine HCL 2% Injection and repackages Avastin l .75mg/0.07 mL, both of which have been used for intravitreal injection, with examples of particulate matter testing described as follows:

• Avastin 1.75mg/0.07 mL (for intravitreal injection), Lot# <Redacted B4>, Manufacturing Date: 7/9/2024, BUD: I 0/7 /2024. Specification for Pa1ticulate Matter:

<Redacted B4> particles contains <Redacted B4> particles/container

However, particulate matter <Redacted B4> ltiH.Jl(Specification: particles/mL) is conducted only for Lidocaine HCL 2% Injection, but not for Avastin 1.75 mg/0.07 mL. Additionally, the specifications for particles <Redacted B4> differ between these products, with no scientific justification provided for this inconsistency.

Observation 5

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically,

A No disinfectant efficacy testing has been conducted for the disinfectants used on supplies and work surfaces. Your firm uses <Redacted B4> to disinfect all surfaces when transferring supplies from lower-grade to higher grade areas. For example, on 9/17/2024, during the production of Avastin 1.75 mg/0.07 mL, Lot <Redacted B4> it was observed operators uses <Redacted B4> to disinfect supplies to be introduced into the ISO 5 LAFWs. Also, <Redacted B4> ,and/or <Redacted B4> are used for routine cleaning in the ISO 5 LAFW s and cleanroom. However, no efficacy studies have been conducted for any of these disinfectants.

B. Cleaning ofthe ISO 5 LAFW was inadequate. Wires used to connect UV lights near the ceiling inside the ISO 5 LAFW were observed not being cleaned after batch processing. For example, on 9/18/2024 operators failed to clean these wires during the production of Avastin 1.75 mg/0.07 mL, Lot# <Redacted B4>. Additionally, uncapped outlets on the ceiling of both LAFWs were present, making thorough cleaning difficult. ...

Read the full 483 (PDF on fda.gov)

Observation 6

Complaint procedures are deficient in that they do not include provisions that allow for the review and determination of an investigation by the quality control unit.

Specifically,

Your firm failed to investigate customer complaints regarding syringes that were underfilled, empty, contained bubbles, or not tightly capped. For example, in 2024, your firm received ten complaints about underfilled syringes, four complaints about empty syringes, and four complaints about syringes with large bubbles. Your firm stated that all syringes had passed visual inspection and suggested the root cause might be improper use by customers. However, no documented investigations were conducted for any of these complaints, and no follow-up communications with customers were reported to verify improper syringe use, other than sending replacements.

Observation 7

Reserve drug product samples are not appropriately identified and representative of each lot or batch of drug product.

Specifically,

Your firm does not maintain retention samples for any finished product batches, nor has your firm established a procedure for the retention of such samples. For example, Your firm received five complaints of endophthalrnitis associated with the use of Avastin in 2024 for the following:

• Avastin 2.5mg/0. lmL, Lot#v<Redacted B4>, Reporting Date: 2/2/2024

• Avastin 2.5mg/0. l mL, Lot # <Redacted B4> Reportiing Date: 4/2/2024

• Avastin 2.5mg/0. l mL, Lot# <Redacted B4>, Reporting Date: 7/29/2024

• Avastin 2.5mg/0. l mL, Lot# <Redacted B4> Reporting Date: 7/29/2024 (same lot for a different patient)

The investigation did not reveal any deficiencies in the operations conducted at your facility, and no definitive root causes have been identified. However, your firm did not retain samples of the finished batch, resulting in no samples being available for further examination and/or testing during the complaint investigation.

Observation 8

Written production and process control procedures are not followed in the execution of production and process control functions.

Specifically,

The visual inspection of a finished batch fails to follow your procedures.

During the visual inspection of Avastin 1.75mg/0.07mL Lot# <Redacted B4> BUD: 12/13/2024, it was observed the <Redacted B4> visual inspection operators did no <Redacted B4> the syringes for visual inspection, as required by SOP-43, 100% Visual Inspection, Version: 3.0, Effective Date: 7/10/2024. Section 5.4.5 of L this SOP states "The syringes shall be carefully <Redacted B4> are visualized <Redacted B4> the syringe can displace the particles and put them l<Redacted B4> making them visible.

Inspection Aug 31, 2022 to Sep 23, 2022: 10 observations

Firm on the cover
RC Outsourcing LLC, 102 E Water St, Lowellville, OH 44436-1117
FEI number
3011967886
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
550 Main Street Cincinnati, OH 45202
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically,

A. Examples include but are not limited to:

1. On 08/31/22, I observed aseptic technicians H, and <Redacted B4>, move from the ISO 7 environment to the ISO 5 a minimum of five (5) times without sanitizing hands appropriately with sterile <Redacted B4>. The general practice observed was that technician <Redacted B4> and (6)( sanitized their gloved hands with sterile H, then dried it with the sterile low-linting wipes. Also, technician <Redacted B4> wiped the Direct Compounding Area (DCA) which is in the ISO 5 classified area with sterile <Redacted B4> using the exposed sterile lint free wipes. These exposed sterile low liniting wipes are located in the ISO 7 classified area. The technician used the same dirty wipes to wipe their gloved hands and immediately entered into the ISO 5 classified area to begin aseptic operations for the repackaging of <Redacted B4> lots I <Redacted B4> and Lot <Redacted B4> respectively.

1 (1:5) (4) I

2. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Protective apparel is not worn as necessaiy to protect drug products from contamination.

Specifically, I observed your aseptic technicians not wearing protective goggles during aseptic operations in ISO 5 Hoods. Parts of the skin around the eyes were exposed in the ISO 5 hoods and I saw aseptic operator <Redacted B4> leaning on <Redacted B4> elbow inside the ISO 5 during aseptic operations and repackaging of <Redacted B4> lots <Redacted B4> and Lot <Redacted B4>.

Observation 3

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically,

A. Your firm's cleaning logs, from January 2022 -August 2022, do not document a contact time for the sporicidal <Redacted B4> used in the cleaning of your ISO 5 and ISO 7 areas. All sterile drug products, including <Redacted B4> and <Redacted B4> are repackaged in ISO 5 hoods <Redacted B4> located in your ISO 7 clean room.

B. Your firm use <Redacted B4> located in the ISO 7 area approximately 6 inches from the opening of the ISO 5 Hood. Per your firm's pharmacist, the <Redacted B4> is covered with a water-resistant case. This <Redacted B4> does not appear to be easily cleanable. You do not have a cleaning specification for the <Redacted B4>. In addition, on 08/31/2022, I observed your aseptic operator touch the <Redacted B4> their gloved hand and and immediately proceed with the aseptic repackaging operations of <Redacted B4> lots <Redacted B4> without appropriately sanitizing their hands prior to entering the ISO 5 Hood.

Observation 4

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

1. You do not perform environmental monitoring which includes active viable air monitoring, surface, non-viable particle and PM for each lot of repackaged <Redacted B4> product since the installation of ISO 5 Hoods <Redacted B4> on May 9th, 2022. Your firm failed to conduct viable air sampling, during aseptic operations for each lot of repackaged <Redacted B4> (Bevacizumab) produced for sterile intraocular injections. I observed that you did not perform active viable air and non-viable articulating at the beginning I and middle while repackaging of <Redacted B4> lots, <Redacted B4> and Lot <Redacted B4> on 08/31/2022. These lots have been released and distribute to your customers. ** THIS IS A REPEAT OBSERVATION**

2 You failed to investigate the 1 CFU recovery from your Active Air <Redacted B4> sample in ISO 5 Hood active air sample which was obtained on 01/11/2022. Per your sample media lot number <Redacted B4> day 6 and 7 samples yielded I CFU and this was not properly investigated. ...

Read the full 483 (PDF on fda.gov)

Observation 5

The flow of components, drug product containers, closures, in-process materials and drug products through the building is not designed to prevent contamination.

Specifically,

A. On 8/31/2022, I observed a gap, approximately 2", at the base of your firm's cleanroom doors (from the non-classified pre-sterilizing area into the ISO 8 anteroom and from the ISO 8 anteroom into the ISO 7 cleanroom). In addition, your firm's ISO 5 LAFH is located directly opposite the ISO 7 clean room exit door. These doors are not airlocked.

a Negative pressure differential excursions were observed. Please refer to OBSERVATION 7 for details.

Observation 6

The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.

Specifically,

A. You pool and commingle different lots of finished re~packaged <Redacted B4> products for sterility and endotoxin testing by your Control testing Lab <REdacted B4> data base does not capture the individual product lots tested for repackaged <Redacted B4>. For example the following but not limited <Redacted B4> syringes lots <Redacted B4> were pooled together and sent for sterility, endotoxin ana particulate testing as Lot <Redacted B4> on 02/10/2022. The Certificate of Analysis (COA) did not have specifics on these <Redacted B4> lots tested. The COA only captured the commingled Lot number. Your QA approved the production batch records without any notation that the two (2 ) <Redacted B4> lots were commingled. The QA accepted the COA from <Redacted B4> failing to verify if the lot numbers were explicitly written on the COA. These 2 <Redacted B4> lots were released without sterility and endotoxin test results of the separate lots and distributed to your customers.

B. ...

Read the full 483 (PDF on fda.gov)

Observation 7

There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been aheady distributed.

Specifically,

A You did not investigate Pressure differential discrepancies in ISO 7 Clean room and the incorrect dating for the logged data between 11/15/2021 to 01/03/2022. The following lots of <Redacted B4>, but not limited to were produced, approved, and distributed to your customers <Redacted B4> <Redacted B4> & <Redacted B4>

B. In addition, your Cleanroom pressure log, dated 8/31/2022, shows at least 29 instances where your pressure differentials were observed to be from O to negative O .11 ranging in duration from 10 min to 30 min.

to 30 min. C. You failed to investigate the 1 CFU recovery from your Active Air <Redacted B4> sample in ISO 5 Hood active air sample which was obtained on 01/11/2022. Sample media lot number <Redacted B4> day 6 and 7 samples yielded 1 CFU and this was not properly investigated. In addition, your SOP P9 .12.1.1 action limit of <Redacted B4> is inadequate.

Observation 8

Changes to written procedures are not drafted, reviewed and approved by the appropriate organizational unit.

Specifically, Your firm does not initiate change controls when necessaiy and in a timely manner. For example, according to your Quality Assurance Director, you did not initiate a change control for the installation of your new ISO 5 Hoods <Redacted B4> with EQ ID: 2022-17913 1 & 2021-1 66295 respectively. These hoods per your Quality Director were installed on May 8th, 2022, in the Clean Room and has been used in the packaging of <Redacted B4> and <Redacted B4> per your Production log from January to August 2022.

Observation 9

Routine of equipment is not performed according to a written program designed to assure proper performance.

Specifically,

1. Pressure gauges monitoring the pressure differential of the processing rooms are not continuously or periodically calibrated.

periodically calibrated.

2. You failed to calibrate your <Redacted B4> Incubator <Redacted B4> periodicallv. You do not have a calibration 41 log for the incubator. fu addition, your temperature ranges of <Redacted B4> for H days per your procedure SOP P3.8.l.6, "PROCEDURE-OPERATING-TECHNOLOGY-INCUBATOR", dated Jan 11, 2022, appear inadequate for your incubation processes.

Observation 10

Your outsourcing facility has not submitted an adverse event report to FDA in accordance with the content and format requirements established through guidance or regulation under 21 CFR 310.305 as required by section 503B(b )(5).

Specifically, your firm did not submit a serious and unexpected adverse event report to FDA within 15 calendar days after first receiving information about the adverse event.

Examples include:

•FDA !CSR ID 2081606, received 2/7/2020, submitted to FDA 3/13/2020

• FDA !CSR ID 2129150, received 4/12/2022, submitted to FDA 5/25/2022

•FDA !CSR ID 2112196, received 4/15/2021, submitted to FDA 6/1/2021

• FDA !CSR ID 2112195, received 4/15/2021, submitted to FDA 6/1/2021

• FDA !CSR ID 2100701, received 10/15/2020, submitted to FDA 12/7/2020

• FDA !CSR ID 2087366, received 6/3/2020, submitted to FDA 7/14/2020

• FDA !CSR ID 2087365, received 6/3/2020, submitted to FDA 7/14/2020

Inspection Mar 27, 2017 to Mar 31, 2017: 9 observations

Firm on the cover
RC Outsourcing L LC, 102 E W ater S t, Lowellville, OH 44436-1 117
FEI number
3011967886
Establishment type on the cover
Outsourcing F acility
FDA district office on the cover
Cincinnati, OH 45237 -3097
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any o f its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically,

1) Between 2/14/2016 and 3/10/2017, 22 positive results of fingertip <Redac ted B4> and surface sam pling were recorded that exceeded <Redacted B4> colon y forming unit. Only 5 investigations were completed; 2 of which resulted in an additional <Redacted B4> cleaning and the remaining 3 h ad n o action taken. The organism obtained was only identified in one investigation. The results o btained included the following: 2 colony forming units on the

ISO 5 surface <Redacted B4> taken on 3 /10/17, 5 colony forming units on the ISO 5 surface <Redacted B4> taken on 1/23/17, 1 colony forming unit (recorded a s "bigger") on the ISO 5 surface <Redacted B4> taken on 03/07/16, 10 colony forming u ...

Read the full 483 (PDF on fda.gov)

Observation 2

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and e quipment to produce aseptic conditions.

Specifically,

1) During cleaning on <Redacted B4>, you cleaned the outside of the ISO 5 hood and then the inside top

of the hood with same cloth. 2) During cleaning on <Redacted B4>, you cleaned ISO 8 side of door between the ISO 7 cleanroom and ISO 8 anteroom, and then cleaned the ISO 7 side of the door with same cloth. 3) During cleaning on <Redacte d B4>, the door between the ISO 7 cleanroom and ISO 8 anteroom r

ooms was left open repeatedly during cleaning and then to air out the ISO 7 room after cleaning. 4) During cleaning on <Redacted B4>, you repeatedly moved from the ISO 8 anteroom to the I SO 7 cleanroom and back again, without changing gowning or gloves. 5) While preparing to enter the ISO 7 cleanroom to repackage Avastin on 3/27/17, you <Redacted B4> with <Redacted B4> and then put a second tub containing more syringes and <Redacted B4> which had been sitting on a wire rack in the ISO 8 anteroom, on top of the syringes in the first tub. ~ 4 ...

Read the full 483 (PDF on fda.gov)

Observation 3

Clothing of personnel engaged in the manufacturing, processing and packing of drug products is not a ppropriate for the duties they perform.

Specifically,

1) During sterile gowning to produce Avastin syringes on 3/27/17, you donned your sterile gown b

efore sitting on a non-sterile bench in the ISO 8 anteroom, donned your sterile boots, washed y our hands with tap water after pushing up the sleeves of your sterile gown, removed your mask, do nned your sterile hood and goggles with the neck of the hood on top of the gown, donned your st erile gloves, and then touched the chest of the gown, the hood, and your goggles with your st erile gloves.

2) During production of Avastin syringes on 3/27/17, you placed the tub of empty syringes, which had previously been sitting on a wire rack in the ISO 8 anteroom, in your lap on top of your sterile gown without disinfecting the outside of the tub.

Observation 4

Each batch of drug product purporting to be pyogen-free is not laboratory tested to determine conformance to such requirements.

Specifically,

There is no routine testing for endotoxin of sterile parenteral drug products manufactured at your firm, including products manufactured using non-sterile active pharmaceutical ingredients, such as vancomycin, phenylephrine, absolute alcohol, and dexamethasone ocular injections.

This is a Repeat Observation from FDA inspection ending on 2/09/2016.

Observation 5

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and written.

Specifically,

6) There is no growth promotion on media prepared by your firm during media fills intended to v alidate aseptic sterile drug processes to demonstrate that the media can support microbial

growth. 7) The <Redacted B4> used to sterilize and depyrogenate glassware and the <Redacted B4> used to sterilize and depyrogenate <Redacted B4> used in sterile parenteral drug production has not been demonstrated to remove endotoxin, despite the fact that the items are <Redacted B4> that has been poured into a non-sterile spray bottle, and then <Redacted B4> in an unclassified room. in addition, no <Redacted B4> are used to verify <Redacted B4>

(6)

sta

bl

is hed for

the depyrogenated sterilized glassware <Redacted B4> and <Reda

cted B4> st ored in tubs in the ISO 8 anteroom that are intende d to be used in sterile parenteral drug production.

This is a Repeat Observation from FDA inspection ending on 2/09/2016.

Observation 6

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

9) Non-viable particulate monitoring is performed <Re dacted B4 > and is not performed under dynamic conditions. 10) Active air sampling is performed <Redacted B 4> and is not performed under dynam ic conditions.

I I

This is a Repeat Observation from FDA inspection ending on 2/09/2016.

Observation 7

Test procedures relative to appropriate laboratory testing for sterility are not followed.

Specifically,

The sterility test you use to test each batch of sterile parenteral drug product you produce uses only <Red acted B4> media; you have not tested any product using <Redacted B4> media to date.

Observation 8

The accuracy and reproducibility of test methods have not been established and documented.

Specifically,

You do not have a program to qualify employees to perform visual inspection for container defects and p articulates on finished sterile parenteral drug products.

Observation 9

Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strengt h, quality and purity.

Specifically,

Visual inspection for container defects and particulates on finished sterile parenteral drug products is a performed by staring at the container directly in front of an <Reda ct ed B4 > with employees performing the examination complaining of the light hurting their eyes and c ausing headaches.

3/ll/2fJ17

JazrrineN!d ~ S9ned by: Jazrrire Stil -5

Linked 483s whose text is not shown

State board of pharmacy records

State board of pharmacy records for Ohio are not checked: the board’s website rejected automated requests and the state’s eLicense lookup answers them with a script check, and this index does not work around blocks.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
AD-0000051Outsourcing Facility-DistributorRC Outsourcing, LLCLOWELLVILLE, OHActive

Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).

LicenseType as the board gives itName on the board recordLocationStatus
5301012343PharmacyRC Outsourcing LLCLowellville, OHActive

FDA’s 503B list

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.